- Home
- LWAY vs ATXS Comparison
LWAY vs ATXS Comparison
Compare LWAY & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWAY
- ATXS
- Stock Information
- Founded
- LWAY 1986
- ATXS 2008
- Country
- LWAY United States
- ATXS United States
- Employees
- LWAY N/A
- ATXS N/A
- Industry
- LWAY Packaged Foods
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- LWAY Consumer Staples
- ATXS Health Care
- Exchange
- LWAY Nasdaq
- ATXS Nasdaq
- Market Cap
- LWAY 376.4M
- ATXS 401.2M
- IPO Year
- LWAY 1987
- ATXS 2015
- Fundamental
- Price
- LWAY $26.47
- ATXS $6.65
- Analyst Decision
- LWAY Hold
- ATXS Strong Buy
- Analyst Count
- LWAY 1
- ATXS 7
- Target Price
- LWAY N/A
- ATXS $32.43
- AVG Volume (30 Days)
- LWAY 45.8K
- ATXS 304.1K
- Earning Date
- LWAY 08-12-2025
- ATXS 08-11-2025
- Dividend Yield
- LWAY N/A
- ATXS N/A
- EPS Growth
- LWAY N/A
- ATXS N/A
- EPS
- LWAY 0.67
- ATXS N/A
- Revenue
- LWAY $188,277,000.00
- ATXS N/A
- Revenue This Year
- LWAY $12.53
- ATXS N/A
- Revenue Next Year
- LWAY $12.08
- ATXS N/A
- P/E Ratio
- LWAY $38.59
- ATXS N/A
- Revenue Growth
- LWAY 12.84
- ATXS N/A
- 52 Week Low
- LWAY $10.06
- ATXS $3.56
- 52 Week High
- LWAY $27.29
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- LWAY 65.90
- ATXS 60.88
- Support Level
- LWAY $24.40
- ATXS $5.94
- Resistance Level
- LWAY $27.00
- ATXS $6.49
- Average True Range (ATR)
- LWAY 0.80
- ATXS 0.34
- MACD
- LWAY 0.11
- ATXS -0.00
- Stochastic Oscillator
- LWAY 80.37
- ATXS 74.74
About LWAY Lifeway Foods Inc.
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.